|Year : 2021 | Volume
| Issue : 3 | Page : 179-183
Intravitreal Ozurdex has no short term influence on choroidal thickness and vascularity index in eyes with diabetic macular edema: A pilot study
Pukhraj Rishi1, Aditya Verma1, Zeeshan Akhtar2, Rupesh Agrawal3, Ashutosh Agrawal1, Rekha Priya Kalluri Bharat1, Ekta Rishi1
1 Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralya, 2Elite School of Optometry, Medical Research Foundation, Sankara Nethralaya, Chennai, Tamil Nadu, India
2 Elite School of Optometry, Medical Research Foundation, Sankara Nethralaya; Srimati Sundari Subramanian Department of Visual Psychophysics, Sankara Nethralya, Chennai, Tamil Nadu, India
3 National Healthcare Group Eye Institute, Tan Tock Seng Hospital; School of Material Science and Engineering, Nanyang Technological University, Singapore
|Date of Submission||05-Jan-2021|
|Date of Decision||08-May-2021|
|Date of Acceptance||21-Jun-2021|
|Date of Web Publication||20-Oct-2021|
Dr. Pukhraj Rishi
Shri Bhagwan Mahavir Vitreoretinal Services, Sankara Nethralya, 18 College Road, Chennai - 600 006, Tamil Nadu
Source of Support: None, Conflict of Interest: None
| Abstract|| |
AIM: To analyze choroidal parameters in eyes with diabetic macular edema (DME) treated with intravitreal Ozurdex.
PATIENTS AND METHODS: Twenty eyes of 14 patients were included in this prospective study. Optical coherence tomography images were obtained before and 8–10 weeks after intravitreal Ozurdex injection; binarized and subfoveal choroidal thickness (SFCT) and choroidal vascularity index (CVI) were calculated.
RESULTS: Mean SFCT (treatment naïve; 242.22 ± 32.87 reduced to 218.10 ± 22.10, P = 0.158 and previously treated; 330.4 ± 56.72 reduced to 328.93 ± 50.55, P = 0.833) and mean CVI (treatment naïve; 0.64 ± 0.03 changed to 0.65 ± 0.04, P = 0.583 and previously treated; 0.65 ± 0.05 reduced to 0.64 ± 0.03, P = 0.208) showed no significant change.
CONCLUSION: Intravitreal Ozurdex showed no significant effects on SFCT and CVI in eyes with DME over short term. Larger studies with longer follow-up may allow a better understanding.
Keywords: Choroid, choroidal thickness, choroidal vascularity index, eye, intravitreal injection, optical coherence tomography, Ozurdex
|How to cite this article:|
Rishi P, Verma A, Akhtar Z, Agrawal R, Agrawal A, Kalluri Bharat RP, Rishi E. Intravitreal Ozurdex has no short term influence on choroidal thickness and vascularity index in eyes with diabetic macular edema: A pilot study. Oman J Ophthalmol 2021;14:179-83
|How to cite this URL:|
Rishi P, Verma A, Akhtar Z, Agrawal R, Agrawal A, Kalluri Bharat RP, Rishi E. Intravitreal Ozurdex has no short term influence on choroidal thickness and vascularity index in eyes with diabetic macular edema: A pilot study. Oman J Ophthalmol [serial online] 2021 [cited 2022 Dec 3];14:179-83. Available from: https://www.ojoonline.org/text.asp?2021/14/3/179/328613
| Introduction|| |
Since the introduction of enhanced depth imaging optical coherence tomography (OCT) in clinical practice and research studies, significant advances have been made in understanding the association of choroidal changes in various retinochoroidal diseases., So far, various studies have relied on the choroidal thickness (CT) to document the changes taking place in choroid in various diseases and in response to therapy.,, The most reliable measurement of the CT is in the subfoveal region, and it definitely overlooks the other vascular changes that might undergo variations as a part of a disease process. The choroidal vascularity index (CVI), i.e., the proportion of the luminal area to the total choroidal area, has recently been proposed to be an excellent quantitative indicator of the vascular status of the choroid in health and disease., This takes precedence considering the fact that histological studies of choroid are unable to yield accurate information about the vascular status of the tissue.
Changes in choroid have been shown to play a pivotal role in pathogenesis of diabetic retinopathy (DR).,,, More importantly, researchers have tried to establish a correlation between choroidal changes and treatment with steroids in eyes with DME. CT is the only parameter that has been investigated in this regard. While some researchers have failed to reach a consensus about the CT in DME,,, others like Sonoda et al. showed a reduction in CT after treatment with steroids. Apart from changes in CT, the effects of steroids on the choroid in these eyes are still less well understood. As the etiology of DME is multifactorial, the effect of various treatment modalities may vary. Nonetheless, there is a paucity in literature regarding the effects of steroids on CT and CVI in these eyes. We analyzed CT and CVI in such eyes treated with sustained release dexamethasone implant over short term.,,
| Patients and Methods|| |
This was a prospective, observational study approved by the Institutional Review Board of Medical Research Foundation, Chennai, India. The study adhered to the tenets of the Declaration of Helsinki. Patients were enrolled between July 2015 and September 2016. Informed consent was obtained from all the patients prior to enrollment. All participants underwent a detailed ocular examination including best-corrected visual acuity using Snellen's chart, slit-lamp biomicroscopy, and dilated fundus evaluation by indirect ophthalmoscopy. The glycemic status, including glycosylated hemoglobin HbA1c if available, was noted.
- Eyes of subjects with diabetes mellitus having DME
- Age >18 years
- Consenting for participation in the study.
- Prior history of retinal laser/antivascular endothelial growth factor (VEGF) injection/intraocular steroid injection in the last 3 months
- History of glaucoma
- Prior surgery like cataract/vitreoretinal surgery
- High myopia >‒6 Diopters.
- Other coexistent retinal diseases.
Intravitreal injection procedure
Written informed consent was obtained prior to injection procedure from all the patients. Pupillary dilatation was carried out with tropicamide eye drops (1%), instilled twice with a gap of 5 min. Proparacaine hydrochloride 1% ophthalmic solution (Paracaine) eye drops were instilled in the conjunctival cul-de-sac 3 times at an interval of 5 min for adequate anesthesia. Povidone iodine eye drops (5%) were instilled twice with a gap of 1 min prior to the injection. The eye was routinely cleaned with povidone iodine skin preparation (10%) and a sterile drape was placed. The dexamethasone implant was injected into the pars plana region, 3.5 mm away in the inferotemporal quadrant by the surgeon, and the same was confirmed with indirect ophthalmoscope fundus examination immediately after the injection. The eye was patched with a sterile eye patch.
Scans were acquired using Swept source OCT (SSOCT, DRI-OCT-1 Atlantis; Topcon, Tokyo, Japan); 12-mm horizontal, vertical, and radial scans centered on the fovea as described in the section of “CT measurement,” were obtained.
Central foveal thickness
The CFT was measured manually using the calipers, by drawing a straight line from the foveal center from the outer edge of internal limiting membrane (ILM) till the inner edge of retinal pigment epithelium (RPE). Foveal center was defined in a B scan passing through the fovea with a hyper-reflective dot echo at the level of ILM.
OCT scans were obtained using SS-OCT (Deep Range Imaging, OCT-1, Atlantis, Topcon, Tokyo, Japan). Scan used for imaging is a 12-mm horizontal, vertical, and radial scan (×2) centered on fovea. Measurements were taken at fovea and at 500 microns interval nasal, temporal, superior, inferior, inferonasal, superotemporal, inferotemporal, and superonasal up to 3000 microns from the fovea [Figure 1]. CT was measured from the base of hyperreflective RPE-Bruch's membrane to the choroid–scleral interface. Six measurements were taken for each quadrant and average values were used for analysis. For each eye, CT was measured at 52 different points. A mean CT for each quadrant (temporal, nasal, superior, inferior, superonasal, inferotemporal, superotemporal, and inferonasal) was obtained by calculating the average value of 6 points for each quadrant. All measurements were manually recorded. Variability in the manual measurement was assessed for 15 random eyes using a horizontal line scan. Measurements were repeated by two masked observers for 13 different locations including subfoveal and 6 different locations nasal and temporal to fovea. Interobserver variability was assessed by comparing the values between two observers. Repeatability of the manual measurements was assessed by repeating the measurements twice at 13 different locations by the same observer using the horizontal line scan with minimum time gap of 1 week. All examination procedures were conducted between 11:00 am and 3:00 pm to control for diurnal variation. The CFT and CT measurements were performed by 2 independent certified graders to assess the intragrader agreement (intraclass correlation coefficient, ICC).
|Figure 1: At presentation, SS-optical coherence tomography image of right eye with diabetic macular edema (a) and binarized image of the same optical coherence tomography (b). Six weeks after intravitreal Ozurdex injection, optical coherence tomography reveals significant reduction of diabetic macular edema (c) and binarized image of the postinjection optical coherence tomography (d)|
Click here to view
Choroidal vascularity index
CVI was calculated using the same raster scan after binarization, as described by Agrawal et al. Images were binarized and CVI was calculated using ImageJ software version 1.50 (National Institute of Health, Bethesda, MD 20892, USA) [Figure 1]. The choroid–scleral interface was delineated with binarization using Niblack's autolocal threshold tool. A subfoveal area of 1.5 mm width, delineated by upper border of RPE and lower border of CSI [Figure 2] was used to calculate the total circumscribed choroidal area (TCA), luminal (dark pixels) area (LA), and the stromal (white pixels) area (SA). CVI was calculated as the proportion of LA to the TCA and was expressed in percentage.
|Figure 2: A subfoveal area of 1.5 mm width (yellow), delineated by upper border at rated perceived exertion and lower border at the choroid-scleral interface, is used to calculate the total circumscribed choroidal area, luminal (dark pixels) area, and the stromal (white pixels) area. Choroidal vascularity index is calculated as the proportion of luminal (dark pixels) area to the total circumscribed choroidal area, expressed in percentage|
Click here to view
Descriptive analysis was employed to compare between treatment naïve and previously treated eyes. The Fisher's exact test or Chi-square test was used to compare frequencies of categorical variables as appropriate. CT and CFT were measured at baseline and at 8–10 weeks after Ozurdex injection and the changes were evaluated using Wilcoxon Signed–Rank test and Mann–Whitney U-test. All the analyses were performed using SPSS version 20.0 (IBM Corp., Armonk, New York, USA) and the statistical significance was tested at 5%.
| Results|| |
Twenty eyes of 14 subjects were recruited in this study. Eleven subjects were male.
The mean age at presentation was 60 ± 5 (range, 52–69) years. All subjects had Type II diabetes, with a mean duration being 14.95 ± 5.8 (range, 2–22) years. Of 20 eyes, 6 eyes (30%) were treatment naïve eyes; 6 eyes (30%) received prior anti-VEGF injections (mean number 1.15 [standard deviation (SD) = ±1.3; range: 0–3]/eye); 3 eyes (15%) received prior Ozurdex injections (mean number 1.35 [SD = ±2.4; range: 0–10]/eye); and 5 eyes (25%) received a combination of both anti-VEGF and Ozurdex injections prior to enrolment into the study. The mean values of clinical parameters before and after intravitreal Ozurdex injection in the study cohort are given in [Table 1]. When compared between treatment naïve and previously treated (Ozurdex, anti-VEGF, and combined injections) eyes [Table 2], there was no statistically significant difference before and after the injection Ozurdex.
|Table 1: Comparison of parameters before and after injection in the study cohort|
Click here to view
|Table 2: Comparison of parameters before and after injection in treatment naïve versus eyes previously treated with Oxurdex™, antivascular endothelial growth factor and combined injections|
Click here to view
However, when the previously treated eyes were grouped together, CMT showed significant reduction following Ozurdex injection in treatment naïve (478.3 ± 257.82-358.87 ± 196.18; P = 0.003) as well as previously treated (597.17 ± 171.38-393.96 ± 171.03; P = 0.05) groups. The corresponding subfoveal CT (treatment naïve; 242.22 ± 32.87-218.10 ± 22.10, P = 0.158 and previously treated; 330.4 ± 56.72-328.93 ± 50.55, P = 0.833) and CVI (treatment naïve; 0.64 ± 0.03-0.65 ± 0.04, P = 0.583 and previously treated; 0.65 ± 0.05-0.64 ± 0.03, P = 0.208) showed no significant change.
| Discussion|| |
The results of this study clearly indicate that the dexamethasone implant had no significant short-term effects on either the thickness or the vascularity index in choroid in eyes with DME. This was true even when the treatment naïve eyes were compared with previously treated eyes grouped together, or analyzed individually (following Ozurdex, anti-VEGF, or both). As inflammation has been shown to play a major role in the pathogenesis of DME, the role of steroids in reducing the macular edema and therefore macular thickness has been well known.,, A few studies have also demonstrated the presence of inflammatory cells in the choroid and dropout of microvessels from the choroid in eyes with DME.,
A spontaneous decrease in CT in eyes with neovascular age-related macular degeneration is well known. A prospective study on Indian patients has also shown reduction in CT in diabetic patients, with or without DR, as compared to healthy subjects. Recent investigators have also shown decreased CT in DME and Proliferative DR., Moreover, a few studies reported a reduction in CT in DME after anti-VEGF therapy and intravitreal triamcinolone injection. However, adequate evidence supporting the changes in choroid after intravitreal dexamethasone injection in such eyes is lacking. While some researchers have failed to reach a consensus about the CT in DME,,, others like Sonoda et al. showed a reduction in CT after treatment with steroids. As the etiology of DME is multifactorial, the effect of various treatment modalities would vary.
The increased expression of inflammatory mediators like intracellular adhesion molecule-1 as well as E- and P-selectins throughout the choroidal vasculature in diabetic eyes shows involvement of choroidal tissue in pathogenesis of DME. Nonetheless, without adequate evidence, clinical involvement of choroidal tissue in response to intravitreal dexamethasone is less well understood. Ours is the first study, which points out the short-term changes taking place in choroid in response to intravitreal Ozurdex™ in such eyes. Since Ozurdex does not appear to influence the subfoveal CT or choroidal vascularity indices in eyes with DME over the short-term, it is unlikely to act as a disease modifying agent in such eyes. The long-term effects of intravitreal dexamethasone injection on choroidal tissue will require a larger longitudinal study.
This study has some limitations. First, the sample size is small. Second, it is a cross-sectional analysis. Larger, prospective trials with adequate numbers in each group and a longer follow-up may highlight choroidal changes in response to intravitreal Ozurdex.
This study analyzes choroidal structures in 20 eyes of 14 subjects with diabetic macular edema (DME) using image binarization on swept source optical coherence tomography. There were no significant differences in subfoveal choroidal thickness or choroidal vascularity indices before and after Ozurdex injection in treatment naïve as well as previously treated eyes over a short-term period.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Spaide RF. Enhanced depth imaging optical coherence tomography of retinal pigment epithelial detachment in age-related macular degeneration. Am J Ophthalmol 2009;147:644-52.
Agrawal R, Gupta P, Tan KA, Cheung CM, Wong TY, Cheng CY. Choroidal vascularity index as a measure of vascular status of the choroid: Measurements in healthy eyes from a population-based study. Sci Rep 2016;6:21090.
Lindner M, Bezatis A, Czauderna J, Becker E, Brinkmann CK, Schmitz-Valckenberg S, et al.
Choroidal thickness in geographic atrophy secondary to age-related macular degeneration. Invest Ophthalmol Vis Sci 2015;56:875-82.
Gupta P, Saw SM, Cheung CY, Girard MJ, Mari JM, Bhargava M, et al.
Choroidal thickness and high myopia: A case-control study of young Chinese men in Singapore. Acta Ophthalmol 2015;93:e585-92.
Koizumi H, Yamagishi T, Yamazaki T, Kawasaki R, Kinoshita S. Subfoveal choroidal thickness in typical age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 2011;249:1123-8.
Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 2008;146:496-500.
Alm A, Bill A. Ocular and optic nerve blood flow at normal and increased intraocular pressures in monkeys (Macaca irus): A study with radioactively labelled microspheres including flow determinations in brain and some other tissues. Exp Eye Res 1973;15:15-29.
Anger EM, Unterhuber A, Hermann B, Sattmann H, Schubert C, Morgan JE, et al.
Ultrahigh resolution optical coherence tomography of the monkey fovea. Identification of retinal sublayers by correlation with semithin histology sections. Exp Eye Res 2004;78:1117-25.
Unsal E, Eltutar K, Zirtiloğlu S, Dinçer N, Ozdoğan Erkul S, Güngel H. Choroidal thickness in patients with diabetic retinopathy. Clin Ophthalmol 2014;8:637-42.
Rewbury R, Want A, Varughese R, Chong V. Subfoveal choroidal thickness in patients with diabetic retinopathy and diabetic macular oedema. Eye (Lond) 2016;30:1568-72.
Farias LB, Lavinsky D, Benfica CZ, da Silva MO, Lavisnky J, Canani LH. Changes in choroidal thickness and volume are related to urinary albumin excretion in type 2 diabetic patients without retinopathy. Clin Ophthalmol 2018;12:1405-11.
Rübsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy. Int J Mol Sci 2018;19:942.
Sonoda S, Sakamoto T, Yamashita T, Otsuka H, Shirasawa M, Kakiuchi N, et al.
Effect of intravitreal triamcinolone acetonide or bevacizumab on choroidal thickness in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci 2014;55:3979-85.
Gerendas BS, Waldstein SM, Simader C, Deak G, Hajnajeeb B, Zhang L, et al.
Three-dimensional automated choroidal volume assessment on standard spectral-domain optical coherence tomography and correlation with the level of diabetic macular edema. Am J Ophthalmol 2014;158:1039-48.
Farias LB, Lavinsky D, Schneider WM, Guimarães L, Lavinsky J, Canani LH. Choroidal thickness in patients with diabetes and microalbuminuria. Ophthalmology 2014;121:2071-3.
Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med 2012;366:1227-39.
Sarda V, Fajnkuchen F, Nghiem-Buffet S, Grenet T, Chaine G, Giocanti-Auregan A. Early efficacy of dexamethasone implant (OZURDEX®
) in diabetic macular edema: Real life study. J Fr Ophtalmol 2017;40:408-13.
Urbančč M, Gardašević Topčić I. Dexamethasone implant in the management of diabetic macular edema from clinician's perspective. Clin Ophthalmol 2019;13:829-40.
Mello Filho P, Andrade G, Maia A, Maia M, Biccas Neto L, Muralha Neto A, et al.
Effectiveness and safety of intravitreal dexamethasone implant (Ozurdex) in patients with diabetic macular edema: A real-world experience. Ophthalmologica 2019;241:9-16.
Akhtar Z, Rishi P, Srikanth R, Rishi E, Bhende M, Raman R. Choroidal thickness in normal Indian subjects using Swept source optical coherence tomography. PLoS One 2018;13:e0197457.
Stewart MW. Corticosteroid use for diabetic macular edema: Old fad or new trend? Curr Diab Rep 2012;12:364-75.
Sonoda Y, Arimura N, Shimura M, Sakamoto T. Early change of central macular thickness after intravitreous triamcinolone or bevacizumab in diabetic macular edema or retinal vein occlusion. Retina 2011;31:290-7.
Zur D, Iglicki M, Loewenstein A. The role of steroids in the management of diabetic macular edema. Ophthalmic Res 2019;62:231-6.
McLeod DS, Lefer DJ, Merges C, Lutty GA. Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol 1995;147:642-53.
Fryczkowski AW, Sato SE, Hodes BL. Changes in the diabetic choroidal vasculature: Scanning electron microscopy findings. Ann Ophthalmol 1988;20:299-305.
Rishi P, Rishi E, Mathur G, Raval V. Ocular perfusion pressure and choroidal thickness in eyes with polypoidal choroidal vasculopathy, wet-age-related macular degeneration, and normals. Eye (Lond) 2013;27:1038-43.
Sudhalkar A, Chhablani JK, Venkata A, Raman R, Rao PS, Jonnadula GB. Choroidal thickness in diabetic patients of Indian ethnicity. Indian J Ophthalmol 2015;63:912-6.
] [Full text]
Kim JT, Lee DH, Joe SG, Kim JG, Yoon YH. Changes in choroidal thickness in relation to the severity of retinopathy and macular edema in type 2 diabetic patients. Invest Ophthalmol Vis Sci 2013;54:3378-84.
Laíns I, Figueira J, Santos AR, Baltar A, Costa M, Nunes S, et al.
Choroidal thickness in diabetic retinopathy: The influence of antiangiogenic therapy. Retina 2014;34:1199-207.
[Figure 1], [Figure 2]
[Table 1], [Table 2]